Conditions of Growth, Economic Analysis - Research Report on Qiagen NV and Onyx Pharmaceuticals, Inc.

RELATED QUOTES

SymbolPriceChange
QGEN18.650.05

HONG KONG--(Marketwire -05/30/12)- Today, www.EquityLeader.com introduced research coverage of Qiagen NV (QGEN) and Onyx Pharmaceuticals, Inc. (ONXX). Full research reports are available to readers at: www.EquityLeader.com/index.php?sm1=QGEN&sm2=ONXX.

With markets in correction mode, investors are looking to quantify an accurate model, weighing positives and negatives of the months ahead. Upcoming negative pressures include China's slowdown, the European recession, the end of the Fed's Operation Twist stimulus program, continued geopolitical risks, election uncertainty, and potential 2013 budget bombshell of tax hikes and spending cuts. Meanwhile, positive offsets are driven by central banks (particularly China) cutting rather than hiking rates, deceleration in fuel and food prices, increase in consumer sentiment and resulting retail sales, signs of improvement in housing sales and new strength in auto production schedules.

Despite the current situation, our team continues to identify high momentum situations with growth potential -- there remains strong opportunity within careful discretion.

Equity Leader has decided to cover Qiagen NV for its current position within the services industry. QIAGEN N.V., (QIAGEN) is a holding company, which provides sample and assay technologies. The consumable products such as sample and assay kits and automated instrumentation systems provides customers to transform raw biological samples into valuable molecular information. A copy of this report detailing Qiagen NV (QGEN) is available at: www.EquityLeader.com/index.php?sm1=QGEN.

Equity Leader is also taking note of Onyx Pharmaceuticals, Inc. for its changing role within the healthcare industry. Onyx Pharmaceuticals, Inc. (Onyx) is a biopharmaceutical company. The Company is developing therapies that target the molecular mechanisms that cause cancer. The Company has built two franchise platforms: one in kinase inhibition and one in proteasome inhibition. To download free research on Onyx Pharmaceuticals, Inc. (ONXX) investors may visit: www.EquityLeader.com/index.php?sm2=ONXX.

About Equity Leader
Whether you are a first time investor or seasoned market professional, Equity Leader provides the resources necessary to simplify your research process. Our focus has always been to empower investors with the information they need to make their own investment decisions.

Contact:
  •  
    Recent Quotes
    Symbol Price Change % ChgChart 
    Your most recently viewed tickers will automatically show up here if you type a ticker in the "Enter symbol/company" at the bottom of this module.
    You need to enable your browser cookies to view your most recent quotes.
  • Recent Quotes News

    •  
      Sign-in to view quotes in your portfolios.

    Trading Center

    Yahoo! Finance on Facebook

    POLL

    What would you like to see out of any potential tax reforms?

    Loading...
    Poll Choice Options